OverviewSuggest Edit

Eagle Pharmaceuticals is a specialty pharmaceutical company, focusing on developing and commercializing injectable products primarily in the critical care and oncology areas. The Company offers argatroban for heparin-induced thrombocytopenia, Ryanodex for malignant hyperthermia, non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head and neck cancers/gastric adenocarcinoma, as well as Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

TypePublic
Founded2007
HQWoodcliff Lake, US
Websiteeagleus.com

Latest Updates

Employees (est.) (Dec 2018)96(-11%)
Job Openings3
Revenue (FY, 2018)$213.3 M(-9%)
Share Price (Oct 2019)$61.9

Key People/Management at Eagle Pharmaceuticals

Scott Tarriff

Scott Tarriff

Chief Executive Officer, Director
Pete Meyers

Pete Meyers

CFO
Steven Krill

Steven Krill

Executive Vice President and Chief Scientific Officer
John LaRocca

John LaRocca

Executive Vice President and General Counsel
Daniel OConnor

Daniel OConnor

Executive Vice President, Biologics and Corporate Development
Adrian Hepner

Adrian Hepner

Executive Vice President and Chief Medical Officer
Show more

Eagle Pharmaceuticals Office Locations

Eagle Pharmaceuticals has offices in Woodcliff Lake and Chicago
Woodcliff Lake, US (HQ)
50 Tice Blvd #315
Chicago, US
Chicago, IL, USA
Show all (2)

Eagle Pharmaceuticals Financials and Metrics

Eagle Pharmaceuticals Revenue

Eagle Pharmaceuticals's revenue was reported to be $213.31 m in FY, 2018
USD

Revenue (Q1, 2019)

49.8m

Gross profit (Q1, 2019)

40.2m

Gross profit margin (Q1, 2019), %

80.8%

Net income (Q1, 2019)

9.0m

EBIT (Q1, 2019)

12.2m

Market capitalization (16-Oct-2019)

920.0m

Closing stock price (16-Oct-2019)

61.9

Cash (31-Mar-2019)

102.1m

EV

822.8m
Eagle Pharmaceuticals's current market capitalization is $920 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

19.1m66.2m189.5m236.7m213.3m

Revenue growth, %

247%186%

Cost of goods sold

15.6m34.3m33.7m42.4m

Gross profit

50.6m155.2m203.0m170.9m
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

5.0m5.8m6.0m5.7m29.6m40.9m37.8m76.8m50.1m63.0m46.6m59.3m51.3m49.8m

Cost of goods sold

3.4m1.6m3.3m3.8m14.6m11.5m10.4m10.8m8.9m4.8m7.2m14.1m8.6m9.6m

Gross profit

1.6m4.2m2.7m2.0m15.0m29.4m27.4m66.0m41.2m58.2m39.4m45.2m42.7m40.2m

Gross profit Margin, %

33%73%44%35%51%72%72%86%82%92%85%76%83%81%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

34.9m79.1m52.8m114.7m78.8m

Accounts Receivable

12.0m26.3m42.2m53.8m66.5m

Inventories

1.2m15.0m11.4m5.1m8.3m

Current Assets

49.7m122.3m109.1m188.7m163.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(18.0m)2.6m81.5m51.9m31.9m

Depreciation and Amortization

13.0k932.0k1.2m

Inventories

(1.3m)(13.8m)12.3m(2.4m)(5.6m)

Accounts Payable

2.9m356.0k10.7m(8.5m)(2.1m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(8.2m)(10.2m)(896.0k)13.1m12.0m22.9m27.4m42.9m2.6m5.3m19.3m9.0m

Depreciation and Amortization

196.0k432.0k657.0k341.0k683.0k918.0k503.0k

Inventories

329.0k2.0m2.3m7.3m7.8m6.4m7.1m3.0m(1.0m)(3.4m)(4.5m)(2.0m)

Accounts Payable

2.5m2.5m5.4m4.8m14.1m10.3m11.4m13.1m4.3m(2.6m)(5.8m)(2.6m)6.3m7.5m6.9m
USDY, 2019

EV/EBIT

67.6 x

EV/CFO

31.4 x

Financial Leverage

1.5 x
Show all financial metrics

Eagle Pharmaceuticals Online and Social Media Presence

Embed Graph

Eagle Pharmaceuticals News and Updates

Research Reveals Potential Growth Cancer Tubulin Inhibitors Market including key players Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals

HTF MI published a new industry research that focuses on Cancer Tubulin Inhibitors market and delivers in-depth market analysis and future prospects of Global Cancer Tubulin Inhibitors market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Eagle Pharmaceuticals Frequently Asked Questions

  • When was Eagle Pharmaceuticals founded?

    Eagle Pharmaceuticals was founded in 2007.

  • Who are Eagle Pharmaceuticals key executives?

    Eagle Pharmaceuticals's key executives are Scott Tarriff, Pete Meyers and Steven Krill.

  • How many employees does Eagle Pharmaceuticals have?

    Eagle Pharmaceuticals has 96 employees.

  • What is Eagle Pharmaceuticals revenue?

    Latest Eagle Pharmaceuticals annual revenue is $213.3 m.

  • What is Eagle Pharmaceuticals revenue per employee?

    Latest Eagle Pharmaceuticals revenue per employee is $2.2 m.

  • Who are Eagle Pharmaceuticals competitors?

    Competitors of Eagle Pharmaceuticals include NeuroVive Pharmaceutical, Acousia Therapeutics and Y-mAbs Therapeutics.

  • Where is Eagle Pharmaceuticals headquarters?

    Eagle Pharmaceuticals headquarters is located at 50 Tice Blvd #315, Woodcliff Lake.

  • Where are Eagle Pharmaceuticals offices?

    Eagle Pharmaceuticals has offices in Woodcliff Lake and Chicago.

  • How many offices does Eagle Pharmaceuticals have?

    Eagle Pharmaceuticals has 2 offices.